Arrhythmic Burden After Bruton's Tyrosine Kinase Inhibitor Initiation and Major Cardiovascular Events

被引：0
|
作者：
Gambril, John A.
Ghazi, Sanam
Sansoterra, Stephen
Ferdousi, Mussammat
Kola-Kehinde, Onaopepo
Ruz, Patrick
Kittai, Adam
Rogers, Kerry
Grever, Michael
Bhat, Seema
Wiczer, Tracy
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Cardio-oncology; Atrial fibrillation; Hematologic Disorders; Arrhythmias;
D O I：
10.1161/circ.148.suppl_1.13214Circulation
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13214
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors
    Ricardo Pineda-Gayoso
    Mohammed Alomar
    Dae Hyun Lee
    Michael G. Fradley
    Current Treatment Options in Oncology, 2020, 21
  • [2] Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors
    Pineda-Gayoso, Ricardo
    Alomar, Mohammed
    Lee, Dae Hyun
    Fradley, Michael G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
  • [3] Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
    Woyach, Jennifer A.
    Furman, Richard R.
    Liu, Ta-Ming
    Ozer, Hatice Gulcin
    Zapatka, Marc
    Ruppert, Amy S.
    Xue, Ling
    Li, Daniel Hsieh-Hsin
    Steggerda, Susanne M.
    Versele, Matthias
    Dave, Sandeep S.
    Zhang, Jenny
    Yilmaz, Ayse Selen
    Jaglowski, Samantha M.
    Blum, Kristie A.
    Lozanski, Arletta
    Lozanski, Gerard
    James, Danelle F.
    Barrientos, Jacqueline C.
    Lichter, Peter
    Stilgenbauer, Stephan
    Buggy, Joseph J.
    Chang, Betty Y.
    Johnson, Amy J.
    Byrd, John C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2286 - 2294
  • [4] Pre-Existing Cardiovascular Disease Increases the Risk of Cardiovascular Adverse Events during Bruton Tyrosine Kinase Inhibitor Therapy
    Turizo, Maria J. Fernandez
    Kim, Eunice
    Asnani, Aarti
    Yankama, Tuyen
    Von Keudell, Gottfried
    Jesus, Caroline Mejias-De
    BLOOD, 2023, 142
  • [5] Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy
    Turizo, Maria J. Fernandez
    Kim, Eunice
    Zhang, Cancan
    Yankama, Tuyen
    Von Keudell, Gottfried
    Sermer, David J.
    Mejias-De Jesus, Caroline
    Asnani, Aarti
    ONCOLOGIST, 2024,
  • [6] Novel leflunomide analog inhibitor of Bruton's tyrosine kinase
    Mahajan, S
    Ghosh, S
    Sudbeck, E
    Zheng, YG
    Downs, S
    Uckun, FM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U283 - U283
  • [7] Real World Cardiovascular Events With Next Generation Bruton's Tyrosine Kinase Inhibitors - An Updated Analysis
    Poliner, Michael C.
    Buck, Benjamin
    Ghazi, Sanam
    Chen, Sunnia
    Gambril, John A.
    Sansoterra, Stephen
    Wiczer, Tracy
    Bhat, Seema
    Azali, Leylah
    Rosen, Lindsay
    Kalathoor, Sujay
    CIRCULATION, 2023, 148
  • [8] Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
    Dostalova, Hana
    Krystof, Vladimir
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (04)
  • [9] Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase
    Kawakami, Y
    Hartman, SE
    Kinoshita, E
    Suzuki, H
    Kitaura, J
    Yao, L
    Inagaki, N
    Franco, A
    Hata, D
    Maeda-Yamamoto, M
    Fukamachi, H
    Nagai, H
    Kawakami, T
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) : 2227 - 2232
  • [10] Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors
    Nazanin Aghel
    Rocio C. Baro Vila
    Michelle Lui
    Christopher Hillis
    Darryl P. Leong
    Current Cardiology Reports, 2023, 25 : 941 - 958
12345